Skip to main content
Top
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

Clinical significance and biological roles of TRIM24 in human bladder carcinoma

Authors: Dongwei Xue, Xiuwei Zhang, Xilin Zhang, Jia Liu, Ning Li, Chunlai Liu, Yili Liu, Ping Wang

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Tripartite motif-containing 24 (TRIM24), also known as transcription intermediary factor 1-alpha (TIF1α), is a chromatin-associated protein which as been has been implicated in carcinogenesis. However, its expression profile and biological roles in human bladder carcinoma has not been investigated. In this study, we examined its expression in 95 bladder cancer specimens. We found that TRIM24 expression was upregulated in 39 of 95 (41.1 %) specimens compared with normal control. TRIM24 overexpression was associated with local invasion and advanced grade of bladder cancer. In addition, we transfected TRIM24 plasmid into BIU-87 cell line and TRIM24 siRNA into 5637 cell line. Colony formation, CCK-8, and transwell assay were used to assess its biological roles in bladder cancer cells. The result showed that TRIM24 could facilitate cancer cell growth and invading ability. Western blot analysis demonstrated that TRIM24 upregulated cyclin D1, cyclin E, p-IκBα, and p-AKT expression, suggesting TRIM24 activates NF-κB and AKT pathways. In addition, NF-κB inhibitor reversed the effect of TRIM24 on cyclin D1. In conclusion, TRIM24 is overexpressed in human bladder cancer and facilitates bladder cancer growth and invasion, possibly through NF-κB and AKT signaling pathways.
Literature
1.
2.
go back to reference Meng XD et al. Increased SPHK1 expression is associated with poor prognosis in bladder cancer. Tumour Biol. 2014;35(3):2075–80.CrossRefPubMed Meng XD et al. Increased SPHK1 expression is associated with poor prognosis in bladder cancer. Tumour Biol. 2014;35(3):2075–80.CrossRefPubMed
3.
go back to reference Liu J et al. Clinical significance of UNC5B expression in bladder cancer. Tumour Biol. 2013;34(4):2099–108.CrossRefPubMed Liu J et al. Clinical significance of UNC5B expression in bladder cancer. Tumour Biol. 2013;34(4):2099–108.CrossRefPubMed
4.
go back to reference Le Douarin B et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 1995;14(9):2020–33.PubMedPubMedCentral Le Douarin B et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 1995;14(9):2020–33.PubMedPubMedCentral
5.
go back to reference Le Douarin B et al. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 1996;15(23):6701–15.PubMedPubMedCentral Le Douarin B et al. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 1996;15(23):6701–15.PubMedPubMedCentral
6.
go back to reference Le Douarin B et al. TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Biochem Soc Trans. 1997;25(2):605–12.CrossRefPubMed Le Douarin B et al. TIF1 alpha: a chromatin-specific mediator for the ligand-dependent activation function AF-2 of nuclear receptors? Biochem Soc Trans. 1997;25(2):605–12.CrossRefPubMed
8.
go back to reference Khetchoumian K et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet. 2007;39(12):1500–6.CrossRefPubMed Khetchoumian K et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet. 2007;39(12):1500–6.CrossRefPubMed
11.
go back to reference Cui Z et al. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS One. 2013;8(5):e63887.CrossRefPubMedPubMedCentral Cui Z et al. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS One. 2013;8(5):e63887.CrossRefPubMedPubMedCentral
12.
14.
go back to reference Zhang LH, et al. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. Oncogene. 2014. Zhang LH, et al. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. Oncogene. 2014.
15.
go back to reference Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98(5):629–35.CrossRefPubMed Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98(5):629–35.CrossRefPubMed
16.
go back to reference Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38(Pt 1):217–22.CrossRefPubMed Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38(Pt 1):217–22.CrossRefPubMed
17.
go back to reference Fristrup N et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 2013;182(2):339–49.CrossRefPubMed Fristrup N et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 2013;182(2):339–49.CrossRefPubMed
18.
go back to reference Hennessy BT et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004.CrossRefPubMed Hennessy BT et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004.CrossRefPubMed
19.
go back to reference Lu B et al. Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway. Tumour Biol. 2012;33(6):2007–17.CrossRefPubMed Lu B et al. Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway. Tumour Biol. 2012;33(6):2007–17.CrossRefPubMed
20.
go back to reference Yu Y et al. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol. 2012;33(2):307–14.CrossRefPubMed Yu Y et al. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol. 2012;33(2):307–14.CrossRefPubMed
21.
go back to reference Man X et al. Clinical significance and biological roles of CARMA3 in human bladder carcinoma. Tumour Biol. 2014;35(5):4131–6.CrossRefPubMed Man X et al. Clinical significance and biological roles of CARMA3 in human bladder carcinoma. Tumour Biol. 2014;35(5):4131–6.CrossRefPubMed
22.
go back to reference Tang ZP et al. Ataxia-telangiectasia group D complementing gene (ATDC) upregulates matrix metalloproteinase 9 (MMP-9) to promote lung cancer cell invasion by activating ERK and JNK pathways. Tumour Biol. 2013;34(5):2835–42.CrossRefPubMed Tang ZP et al. Ataxia-telangiectasia group D complementing gene (ATDC) upregulates matrix metalloproteinase 9 (MMP-9) to promote lung cancer cell invasion by activating ERK and JNK pathways. Tumour Biol. 2013;34(5):2835–42.CrossRefPubMed
Metadata
Title
Clinical significance and biological roles of TRIM24 in human bladder carcinoma
Authors
Dongwei Xue
Xiuwei Zhang
Xilin Zhang
Jia Liu
Ning Li
Chunlai Liu
Yili Liu
Ping Wang
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3393-3

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine